Aminophylline

證據等級: L5

預測適應症: 10 個

Aminophylline: From Bronchospasm to Migraine Disorder

One-Sentence Summary

Aminophylline is a methylxanthine derivative and adenosine receptor antagonist, historically established as a bronchodilator for asthma, COPD, and apnea of prematurity. The TxGNN model predicts it may be effective for Migraine Disorder, with 0 clinical trials and 6 publications currently supporting this direction. Evidence remains at the mechanistic and review level (L4), qualifying this as an emerging research hypothesis rather than a clinically validated indication.

Quick Overview

Item	Content
Original Indication	No authorization data available; established pharmacological use as bronchodilator (asthma, COPD, apnea of prematurity)
Predicted New Indication	Migraine Disorder
TxGNN Prediction Score	99.88%
Evidence Level	L4
Saudi Arabia Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available in this evidence pack. Based on established pharmacology, aminophylline is a soluble salt of theophylline and ethylenediamine. Its primary actions are non-selective phosphodiesterase (PDE) inhibition — which elevates intracellular cAMP — and competitive antagonism at adenosine receptors (A1, A2A, A2B). It is this adenosine receptor antagonism that forms the mechanistic backbone of the migraine prediction.

Adenosine, particularly via A2A receptor activation, is known to cause selective intracranial vasodilation and sensitize trigeminal nociceptive fibers — two cardinal features of migraine pathophysiology. A 2023 clinical review (PMID 38059379) proposes that migraine may be partly driven by impaired brain energy metabolism in a context of pathologically elevated adenosine, and documents observational evidence of strong analgesic relief with aminophylline, including in post-dural puncture headache. An in vitro study (PMID 219563) further demonstrated that adenosine and adenine compounds markedly dilate feline and human pial arteries but not extracranial vessels, pointing to a selective intracranial vascular role.

Perhaps the most compelling evidence comes from reverse pharmacology: regadenoson, a selective A2A adenosine receptor agonist used during cardiac stress imaging, was shown to trigger a hemiplegic migraine episode (PMID 34308528) — and aminophylline is routinely used to reverse regadenoson's effects. If A2A agonism provokes migraine, then A2A antagonism by aminophylline may attenuate it. This indirect logic is mechanistically coherent, though not yet tested in a prospective migraine trial.

Clinical Trial Evidence

Currently no related clinical trials registered for aminophylline in migraine disorder.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38059379	2023	Review / Clinical Analysis	Pain Management	Proposes adenosine excess and impaired brain energy metabolism as migraine drivers; documents observational evidence that aminophylline provides strong therapeutic relief in pain and post-dural puncture headache — a closely related adenosine-mediated headache syndrome
34308528	2022	Case Report	Journal of Nuclear Cardiology	Hemiplegic migraine episode triggered by regadenoson (selective A2A agonist) during myocardial perfusion imaging; aminophylline used as reversal agent — provides reverse-pharmacology support for A2A antagonism as a migraine intervention strategy
219563	1979	In Vitro / Mechanistic	Stroke	Adenosine and adenine compounds markedly dilate feline and human pial arteries in vitro, with effect absent in extracranial vessels; supports adenosine's selective intracranial vascular role and the potential anti-vasodilatory effect of adenosine antagonists in migraine
7728647	1995	Case Report	Canadian Journal of Cardiology	Patient with Syndrome X presenting adenosine-mediated cardiac pain ("myocardial migraine") triggered by dipyridamole; supports the broader concept that adenosine signaling drives episodic nociceptive events reversible by methylxanthines
14168418	1964	Historical Review	Aggiornamenti Clinicoterapeutici	Historical Italian review of medical headache treatment including xanthine derivatives; provides early conceptual background for xanthine use in headache

Safety Considerations

Please refer to the package insert for safety information.

Note: Drug interaction data was not found in the DDI database for aminophylline, and key warnings/contraindications were not retrievable in this evidence pack. Given that theophylline (the active moiety of aminophylline) has a narrow therapeutic index, serum level monitoring is standard practice. This is a clinically important safety consideration for any new indication development.

Conclusion and Next Steps

Decision: Hold

Rationale: The adenosine receptor antagonism hypothesis linking aminophylline to migraine relief is biologically coherent and supported by one recent clinical review alongside compelling reverse-pharmacology case evidence — but the complete absence of registered clinical trials and reliance on L4 (mechanistic/review-level) evidence prevents recommendation for clinical deployment at this stage.

To proceed, the following is needed:

Clinical trial initiation: A proof-of-concept Phase 1/2 study evaluating aminophylline in acute migraine treatment (IV or oral formulation), particularly in post-dural puncture headache as a bridging model
MOA documentation: Formal retrieval of DrugBank pharmacology data (adenosine receptor binding affinities, PDE isoform selectivity) to strengthen mechanistic dossier
Safety package: Retrieval of package insert warnings, contraindications, and key drug interactions — especially with triptans, ergotamines, NSAIDs, and other common migraine medications
Therapeutic index assessment: Theophylline serum monitoring requirements must be evaluated for feasibility in a migraine outpatient setting, where narrow therapeutic windows may be a practical barrier
Formulation strategy: Determine whether an oral sustained-release or IV route is appropriate for migraine (acute vs. prophylactic use case) given the pharmacokinetic profile of theophylline
Saudi Arabia regulatory pathway: As aminophylline is currently not marketed in Saudi Arabia, a full new drug registration or compassionate use pathway would be required before any clinical program can proceed locally
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.